Profiles

Keywords
Last Name
Institution

Agne Paner

TitleAssistant Professor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Hematology/Oncology/Cell Therapy
AddressChicago IL 60612
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Weisel K, Dimopoulos MA, San-Miguel J, Paner A, Engelhardt M, Taylor F, Lord-Bessen J, Yip C, Greenwood M, Tang J, Cavo M. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial. Hemasphere. 2023 Mar; 7(3):e843. PMID: 36860268.
      View in: PubMed
    2. Idowu A, Tung L, Chu C, Skeete J, Paner A, Okwuosa T. NEW-ONSET CARDIAC AMYLOIDOSIS WHILE IN REMISSION FROM SYSTEMIC AL AMYLOIDOSIS. Eur J Case Rep Intern Med. 2023; 10(2):003768. PMID: 36970162.
      View in: PubMed
    3. Nadeem O, Mateos MV, Efebera YA, Paner A, Larocca A, Rodr?guez-Otero P, Leleu X, Richardson PG. Melphalan flufenamide for relapsed/refractory multiple myeloma. Drugs Today (Barc). 2022 Aug; 58(8):407-423. PMID: 35983927.
      View in: PubMed
    4. Williams MD, Thomas J, Paner A, Chan EY, Hollinger EF, Schadde E, Hertl M, Santos CAQ, Olaitan OK. Can Donor-Derived Cell-Free DNA Detect Graft-Versus-Host Disease in Solid Organ Transplantation: A Case Report. Transplant Proc. 2022 Jan-Feb; 54(1):176-179. PMID: 34961600.
      View in: PubMed
    5. Larocca A, Leleu X, Touzeau C, Blad? J, Paner A, Mateos MV, Cavo M, Maisel C, Alegre A, Oriol A, Raptis A, Rodriguez-Otero P, Mazumder A, Laubach J, Nadeem O, Sandberg A, Orre M, Torr?ng A, Bakker NA, Richardson PG. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. Br J Haematol. 2022 02; 196(3):639-648. PMID: 34671975.
      View in: PubMed
    6. Masood A, Christ T, Asif S, Rajakumar P, Gustafson BA, Shune LO, Salahudeen A, Nedvad D, Nanua S, Paner A, Kuzel TM, Levy M, Subramanian J, Raza S. Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition. NPJ Genom Med. 2021 Mar 17; 6(1):23. PMID: 33731690.
      View in: PubMed
    7. Richardson PG, Oriol A, Larocca A, Blad? J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767. PMID: 33296242.
      View in: PubMed
    8. Oriol A, Larocca A, Leleu X, Hajek R, Hassoun H, Rodr?guez-Otero P, Paner A, Schjesvold FH, Gullbo J, Richardson PG. Melflufen for relapsed and refractory multiple myeloma. Expert Opin Investig Drugs. 2020 Oct; 29(10):1069-1078. PMID: 32924646.
      View in: PubMed
    9. Zimmerman A, Planek MIC, Chu C, Oyenusi O, Paner A, Reding K, Skeete J, Clark B, Okwuosa TM. Exercise, cancer and cardiovascular disease: what should clinicians advise? Cardiovasc Endocrinol Metab. 2021 Jun; 10(2):62-71. PMID: 34113793.
      View in: PubMed
    10. Dhakal B, Miller S, Rein L, Pathak LK, Gloria L, Szabo A, Giri S, Chhabra S, Hamadani M, Paner A, Padmanabhan A, Janz S, D'Souza A, Hari P. Trends in the use of therapeutic plasma exchange in multiple myeloma. J Clin Apher. 2020 Aug; 35(4):307-315. PMID: 32516865.
      View in: PubMed
    11. Rowinsky EK, Paner A, Berdeja JG, Paba-Prada C, Venugopal P, Porkka K, Gullbo J, Linder S, Loskog A, Richardson PG, Landgren O. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma. Invest New Drugs. 2020 10; 38(5):1448-1453. PMID: 32125598.
      View in: PubMed
    12. Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020 05; 41:100643. PMID: 31818702.
      View in: PubMed
    13. Gilmore BA, Rodby RA, Cimbaluk D, Venugopal P, Patel P, Barton K, Hagen P, Rodriguez T, Sumoza L, Bishop MR, Dhakal B, Hari P, Paner A. When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):e251-e258. PMID: 30987953.
      View in: PubMed
    14. Paner A, Okwuosa TM, Richardson KJ, Libby EN. Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities. Expert Rev Hematol. 2018 12; 11(12):957-973. PMID: 30339769.
      View in: PubMed
    15. Derman BA, Reiser J, Basu S, Paner A. Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. Int J Nephrol. 2018; 2018:4654717. PMID: 30254762.
      View in: PubMed
    16. Sethi S, Paner A, Okwuosa T, Jandali D, Dua S, Wiet RM, Ghai R. Light Chain Amyloidosis Presenting as Bilateral External Auditory Canal Obstructing Masses. Otol Neurotol. 2018 09; 39(8):e749-e751. PMID: 29957672.
      View in: PubMed
    17. Okwuosa TM, Prabhu N, Patel H, Kuzel T, Venugopal P, Williams KA, Paner A. The Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (or?Onco-Cardiology) and?Call?to?Action. J Am Coll Cardiol. 2018 07 10; 72(2):228-232. PMID: 29976296.
      View in: PubMed
    Paner's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (74) concept(s)
    _
    Co-Authors Expand Description
    See all (11) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department